Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib-Reference-Cited by-同舟云学术

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib

Published:2013-03 Issue:4 Volume:108 Page:887-900
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Beuselinck B,Karadimou A,Lambrechts D,Claes B,Wolter P,Couchy G,Berkers J,Paridaens R,Schöffski P,Méjean A,Verkarre V,Lerut E,de la Taille A,Tourani J-M,Bigot P,Linassier C,Négrier S,Berger J,Patard J-J,Zucman-Rossi J,Oudard S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2012548.pdf

Reference20 articles.

1. Beuselinck B, Oudard S, Rixe O, Wolter P, Blesius A, Ayllon J, Elaidi R, Schöffski P, Barrascout E, Morel A, Escudier B, Lang H, Zucman-Rossi J, Medioni J (2011) Negative impact of bone metastasis on outcome in clear cell renal cell carcinoma treated with Sunitinib. Ann Oncol 22: 794–800

2. Dietrich CG, Geier A, Oude Elferink RPJ (2003) ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52: 1788–1795

3. Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, Del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12: 1143–1150

4. Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI (2009) Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 27: 235–241

5. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK (2009) Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27: 5794–5799

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of genetic polymorphisms in vascular endothelial-related genes on the clinical outcome of axitinib in patients with metastatic renal cell carcinoma;Cancer Biology & Therapy;2024-02-07

2. Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma;Cancer Drug Resistance;2023-12-28

3. The Utility of Genomics and Functional Imaging to Predict Sunitinib Pharmacokinetics and Pharmacodynamics: The Predict Su Study;2023-06-26

4. Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers;Drug Resistance Updates;2023-03

5. Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma;Cancers;2023-01-05